Elisabet de Los Pinos - 02 Nov 2021 Form 4 Insider Report for Aura Biosciences, Inc. (AURA)

Role
President and Chief Executive Officer, Director
Signature
/s/ Julie Feder, as Attorney-in-Fact
Issuer symbol
AURA
Transactions as of
02 Nov 2021
Net transactions value
$0
Form type
4
Filing time
02 Nov 2021, 16:13:26 UTC
Previous filing
28 Oct 2021
Next filing
02 Nov 2022
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction AURA Common Stock Conversion of derivative security $0 +4,552 +3.6% $0.000000 131,412 02 Nov 2021 By EdIP Revocable Trust F1, F2
holding AURA Common Stock 74,357 02 Nov 2021 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction AURA Series A-1 Preferred Stock Conversion of derivative security -3,042 -100% 0 02 Nov 2021 Common Stock 3,042 By EdIP Revocable Trust F1, F2
transaction AURA Series A-2 Preferred Stock Conversion of derivative security -1,510 -100% 0 02 Nov 2021 Common Stock 1,510 By EdIP Revocable Trust F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The Series A-1 and Series A-2 Preferred Stock converted into the number of shares of Common Stock of the Issuer upon the closing of the Issuer's Initial Public Offering. These amounts reflect a 1-for-13.700 reverse split which became effective on October 22, 2021.
F2 The shares are held by the Elisabet de los Pinos Revocable Trust U/D/T dated April 8, 2016, of which the Reporting Person is a trustee.

Remarks:

President and Chief Executive Officer